Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

WANG Wanwan; YE Jun; CHENG Hai; YAO Wei; LIU Guiling

doi:10.6039/j.issn.1001-0408.2025.14.16

您当前的位置：

首页 >

文章列表页 >

Efficacy and safety of ruxolitinib in the treatment of myelofibrosis

更新时间：2025-09-24

- Efficacy and safety of ruxolitinib in the treatment of myelofibrosis
- ZHONGGUO YAOFANG Vol. 36, Issue 14, Pages: 1781-1785(2025)
- 作者机构：
  
  1.蚌埠市第三人民医院血液内科，安徽蚌埠　233000
  2.徐州医科大学附属医院血液内科，江苏徐州　221000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.14.16
  CLC： R559;R969.3
- Received：16 December 2024，
  
  Revised：2025-06-07，
  
  Accepted：11 June 2025，
  
  Published：30 July 2025
- 稿件说明：
移动端阅览
王菀菀,叶隽,程海,等.芦可替尼治疗骨髓纤维化的疗效与安全性[J].中国药房,2025,36(14):1781-1785.

WANG Wanwan,YE Jun,CHENG Hai,et al.Efficacy and safety of ruxolitinib in the treatment of myelofibrosis[J].ZHONGGUO YAOFANG,2025,36(14):1781-1785.
王菀菀,叶隽,程海,等.芦可替尼治疗骨髓纤维化的疗效与安全性[J].中国药房,2025,36(14):1781-1785. DOI： 10.6039/j.issn.1001-0408.2025.14.16.

WANG Wanwan,YE Jun,CHENG Hai,et al.Efficacy and safety of ruxolitinib in the treatment of myelofibrosis[J].ZHONGGUO YAOFANG,2025,36(14):1781-1785. DOI： 10.6039/j.issn.1001-0408.2025.14.16.

摘要

目的

探究芦可替尼治疗骨髓纤维化（MF）的疗效和安全性。

方法

回顾性收集2018年9月至2024年4月于蚌埠市第三人民医院就诊且规范使用芦可替尼超过6个月的42例MF患者资料。分析治疗前后患者的临床症状评分、脾脏缩小情况和MF分级情况，并记录关联性评价结果为“肯定”“很可能”“可能有关”的不良反应的发生情况，随访患者的生存情况。

结果

治疗6个月后，患者的各单项临床症状评分及总分均较治疗前显著降低（

＜0.05），脾脏长径、厚径均较治疗前显著缩短（

＜0.05）。5例患者的MF分级较基线下降1级，1例由MF-2级下降至MF-0级，14例MF分级未发生变化。不良反应以贫血（26例次）、血小板减少（14例次）、感染（11例次）、胃肠道不适（9例次）为主。39例患者存活，生存率为92.86%。

结论

芦可替尼能有效改善MF患者的临床症状，缩小脾脏，稳定甚至改善MF分级，有望为MF患者带来长期生存获益；不良反应主要表现为贫血、血小板减少、感染及胃肠道不适。

Abstract

OBJECTIVE

To explore the efficacy and safety of ruxolitinib in the treatment of myelofibrosis （MF）.

METHODS

A retrospective collection of data was conducted on 42 MF patients who were treated with ruxolitinib in a standardized manner for more than 6 months in the Third People’s Hospital of Bengbu from September 2018 to April 2024. The clinical symptom scores， spleen size reduction， and MF grading of the patients before and after treatment were analyzed. Additionally， the occurrence of adverse reactions with a causality assessment result of “definite”“probable” or “possible” was recorded. The patients’ survival status was followed up.

RESULTS

After 6 months of treatment， both clinical symptom scores and the total score were significantly decreased than before treatment （

＜0.05）. The length and thickness of the spleen were significantly shorter than before treatment （

＜0.05）. MF classification in 5 patients decreased by 1 level compared with baseline， 1 case was level 2 and dropped to level 0， 14 patients remained stable. The main adverse reactions were anemia （26 cases）， thrombocytopenia （14 cases）， infection （11 cases）， and gastrointestinal discomfort （9 cases）. Thirty-nine patients survived， with a survival rate of 92.86%.

CONCLUSIONS

Ruxolitinib can effectively improve the clinical symptoms of patients with MF， shrink the spleen， stabilize and even improve MF grading， and holds promise for bringing long-term survival benefits to MF patients. Adverse reactions are mainly anemia， thrombocytopenia， infection and gastrointestinal discomfort.

关键词

Keywords

references

MEAD A J ， MULLALLY A . Myeloproliferative neoplasm stem cells [J ] . Blood ， 2017 ， 129 （ 12 ）： 1607 - 1616 .

TEFFERI A ， GUGLIELMELLI P ， LARSON D R ， et al . Long-term survival and blast transformation in molecularly annotated essential thrombocythemia，polycythemia vera，and myelofibrosis [J ] . Blood ， 2014 ， 124 （ 16 ）： 2507 - 2513 .

ZAHR A A ， SALAMA M E ， CARREAU N ， et al . Bone marrow fibrosis in myelofibrosis：pathogenesis，prognosis and targeted strategies [J ] . Haematologica ， 2016 ， 101 （ 6 ）： 660 - 671 .

VERSTOVSEK S ， GOTLIB J ， MESA R A ， et al . Long-term survival in patients treated with ruxolitinib for myelofibrosis：COMFORT-Ⅰ and-Ⅱ pooled analyses [J ] . J Hematol Oncol ， 2017 ， 10 （ 1 ）： 156 .

中华医学会血液学分会白血病淋巴瘤学组，肖志坚，王建祥 . 原发性骨髓纤维化诊断与治疗中国指南：2019年版 [J ] . 中华血液学杂志， 2019 ， 40 （ 1 ）： 1 - 7 .

中国临床肿瘤学会（CSCO） . CSCO恶性血液病诊疗指南：2024 [M ] . 北京：人民卫生出版社， 2024 ： 345 - 368 .

VERSTOVSEK S ， MESA R A ， GOTLIB J ， et al . A double-blind，placebo-controlled trial of ruxolitinib for myelofibrosis [J ] . N Engl J Med ， 2012 ， 366 （ 9 ）： 799 - 807 .

HARRISON C N ， VANNUCCHI A M ， KILADJIAN J J ， et al . Long-term findings from COMFORT-Ⅱ，a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis [J ] . Leukemia ， 2016 ， 30 （ 8 ）： 1701 - 1707 .

金洁，杜欣，周道斌，等 . JAK抑制剂芦可替尼治疗中国骨髓纤维化患者的疗效和安全性：A2202随访一年结果 [J ] . 中华血液学杂志， 2016 ， 37 （ 10 ）： 858 - 863 .

MASAROVA L ， MESA R A ， HERNÁNDEZ-BOLUDA J C ， et al . Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported [J ] . Leuk Res ， 2020 ， 91 ： 106338 .

张奇，崔渤莉，费海荣，等 . 芦可替尼治疗血小板减少骨髓纤维化的有效性和安全性 [J ] . 青岛大学学报（医学版）， 2025 ， 61 （ 1 ）： 29 - 33 .

US Department of Health and Human Services ， National Institutes of Health ， National Cancer Institute . Common Terminology Criteria for Adverse Events（CTCAE），version 4.03 [EB/OL ] . [ 2024-12-01 ] . http：//www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf http://www.eortc.be/services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5x7.pdf .

WHO . The use of the WHO-UMC system for standardised case causality assessment [EB/OL ] . [ 2024-12-02 ] . https：//www.who.int/publications/m/item/WHO-causality-assess-ment https://www.who.int/publications/m/item/WHO-causality-assess-ment .

KVASNICKA H M ， THIELE J ， BUESO-RAMOS C E ， et al . Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis [J ] . J Hematol Oncol ， 2018 ， 11 （ 1 ）： 42 .

张雪皎，王跃，谭云山，等 . 芦可替尼治疗骨髓纤维化患者的疗效及其预测模型 [J ] . 中国癌症防治杂志， 2021 ， 13 （ 4 ）： 370 - 375 .

JUNG C W ， SHIH L Y ， XIAO Z J ， et al . Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis [J ] . Leuk Lymphoma ， 2015 ， 56 （ 7 ）： 2067 - 2074 .

HOW J ， HOBBS G S . A practical guide for using myelofibrosis prognostic models in the clinic [J ] . J Natl Compr Canc Netw ， 2020 ， 18 （ 9 ）： 1271 - 1278 .

罗洁，谭雅娴，黄继贤，等 . 芦可替尼治疗骨髓纤维化阶段性疗效及安全性评估 [J ] . 实用医学杂志， 2021 ， 37 （ 9 ）： 1187 - 1192 .

GUPTA V ， GRIESSHAMMER M ， MARTINO B ， et al . Poster presentation at 23rd congress of the European Hematology Association [M ] . Stockholm ： Sweden ， 2018 ： PF616 .

于淮海，孙雨飞，金昌洙，等 . 信号传导及转录激活因子信号通路在自然杀伤细胞研究中的进展 [J ] . 转化医学杂志， 2018 ， 7 （ 3 ）： 189 - 193 .

YANG Y F ， LUO H M ， ZHENG Y H ， et al . Low-dose ruxolitinib shows effective in treating myelofibrosis [J ] . Ann Hematol ， 2021 ， 100 （ 1 ）： 135 - 141 .

ELLI E M ， BARATÈ C ， MENDICINO F ， et al . Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib [J ] . Front Oncol ， 2019 ， 9 ： 1186 .

BARONE M ， CATANI L ， RICCI F ， et al . The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis [J ] . Oncoimmunology ， 2020 ， 9 （ 1 ）： 1782575 .

AL-ALI H K ， GRIESSHAMMER M ， FOLTZ L ， et al . Primary analysis of JUMP，a phase 3b，expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis，including those with low platelet counts [J ] . Br J Haematol ， 2020 ， 189 （ 5 ）： 888 - 903 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of doxycycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children under 8 years of age

Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors combined with bevacizumab in the treatment of advanced non-small cell lung cancer

Clinical observation of vonoprazan-based triple therapy in treatment-naive patients with Helicobacter pylori infection

Comparison of the efficacy and safety between the drug winning the bidding for centralized procurement and the original drug of ticagrelor in acute coronary syndrome patients after percutaneous coronary intervention

Clinical observation of venetoclax combined with homoharringtonine and cytarabine in the treatment of acute myeloid leukemia

Related Author

ZHENG Jishan

CHEN Yanyan

LI Shanshan

SHEN Longhui

ZOU Jiafeng

ZHAO Jiufeng

SUN Chengxin

LUO Hongmei

Related Institution

Dept. of Pharmacy， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Paediatrics， Women and Children’s Hospital Affiliated to Ningbo University

Dept. of Pharmacy， the Affiliated Hospital of Zunyi Medical University

School of Pharmacy， Zunyi Medical University

Dept. of Pharmacy， the University of Hong Kong-Shenzhen Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰